AstraZeneca Financial Statements From 2010 to 2024
| ZEG Stock | EUR 128.30 0.85 0.66% |
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as , as well as many indicators such as . AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
AstraZeneca |
AstraZeneca PLC Company Shares Outstanding Analysis
AstraZeneca PLC's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current AstraZeneca PLC Shares Outstanding | 1.55 B |
Most of AstraZeneca PLC's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, AstraZeneca PLC has 1.55 B of shares currently outstending. This is much higher than that of the Healthcare sector and 21.94% higher than that of the Drug Manufacturers - Major industry. The shares outstanding for all Germany stocks is 171.03% lower than that of the firm.
AstraZeneca PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.AstraZeneca PLC is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AstraZeneca PLC is roughly 1.55 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.About AstraZeneca PLC Financial Statements
AstraZeneca PLC stakeholders use historical fundamental indicators, such as AstraZeneca PLC's revenue or net income, to determine how well the company is positioned to perform in the future. Although AstraZeneca PLC investors may analyze each financial statement separately, they are all interrelated. For example, changes in AstraZeneca PLC's assets and liabilities are reflected in the revenues and expenses on AstraZeneca PLC's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AstraZeneca PLC. Please read more on our technical analysis and fundamental analysis pages.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. AstraZeneca PLC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 64400 people.
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.